Larimar Therapeutics Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Larimar Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $15.11. The average 1-year stock price forecast is 315.11% higher than the current stock price, while the lowest is $7.00 (+92.31%) and the highest is $26 (+614.29%).

Price Target: $15.11 (+315.11%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$7.00	$15.11	$13	$26
Change	+92.31%	+315.11%	+257.14%	+614.29%

Analyst Ratings

The average analyst rating for Larimar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	10	9	10	10	10	8
Buy	1	1	1	1	1	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	10	11	11	11	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Tessa Romero J.P. Morgan	J.P. Morgan	Buy Initiates $9	Buy	Initiates	$9	+147.25%	May 27, 2026
Myles Minter William Blair	William Blair	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	May 18, 2026
Laura Chico Wedbush	Wedbush	Buy Maintains $12	Buy	Maintains	$12	+229.67%	May 18, 2026
Francois Brisebois LifeSci Capital	LifeSci Capital	Buy Reiterates $25	Buy	Reiterates	$25	+586.81%	May 15, 2026
Samantha Semenkow Citi	Citi	Buy Reiterates $14	Buy	Reiterates	$14	+284.62%	Mar 20, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

58.30M

EPS This Year

-1.62

from -2.27

EPS Next Year

-1.23

from -1.62

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-50.47M	-36.53M	-41.76M	-90.89M	-172.50M	-166.63M
Net Income	-50.64M	-35.36M	-36.95M	-80.60M	-165.67M	-157.09M
EPS	-	-	-	-	-2.27	-1.62
Free Cash Flow	-23.09M	-14.35M	-20.84M	-42.05M	-53.47M	-182.00M
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-1.43
Avg	-1.62
Low	-1.82

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-